Hamburg based PLS-Design GmbH receives BioChancePLUS funding
The German Federal Ministry for education and Research funds a project for standardizing allergy tests to control reliably the progress of allergen-desensitizing treatment. A problem with today's allergy tests is the lack of comparability between tests of different suppliers who only aim at a standardization of their own test systems. Thus, a doctor cannot adopt the results of different tests as a reliable basis for the treatment of patients even if this would be preferable.
PLS-Design GmbH, Hamburg, has now found a practicable solution. With the support of the North German Life Science Agency Norgenta the company has successfully applied for funding from the German Federal Ministry for Education and Research for this project. The goal is a standardized diagnostic tool for reliably controlling the progress of allergen-desensitizing treatment. The new method will initially only be applied for insect venom allergies. After all, the new approach will help approximately 3 million affected patients with an improved therapy.
The research project funded with 370,000 EUR is effected in a cooperation of the Hamburg based biotech company with the University of Hamburg, the Technical University of Munich as well as the University of Anhalt in Bernburg. PLS-Design will produce for the first time a number of recombinant human IgE-antibodies that are similar to those in patients' blood. These specific antibodies will be used as components of artificial patient sera for a general standardization of allergy tests.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous